New antibody combo aims to shrink tough tumors
NCT ID NCT07158918
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 33 times
Summary
This study tests a new drug called ABL103 combined with pembrolizumab (with or without a chemotherapy called taxane) in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and can shrink or control the tumors. About 65 adults with various advanced cancers will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
NOT_YET_RECRUITINGSeoul, 05505, South Korea
-
PASO Medical
NOT_YET_RECRUITINGFrankston, Victoria, 3199, Australia
-
Samsung Medical Center
NOT_YET_RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam, 13620, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
UH Cleveland Medical Center
NOT_YET_RECRUITINGCleveland, Ohio, 44106, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.